2172 Stock Overview
Engages in the research and development, production, and sale of neuro-interventional medical devices in the People’s Republic of China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 2172 from our risk checks.
MicroPort NeuroScientific Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$9.97 |
| 52 Week High | HK$14.18 |
| 52 Week Low | HK$6.21 |
| Beta | -0.27 |
| 11 Month Change | 26.04% |
| 3 Month Change | 42.63% |
| 1 Year Change | -16.36% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -38.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2172 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | 16.3% | 17.0% | 9.6% |
| 1Y | -16.4% | -20.2% | 27.2% |
Return vs Industry: 2172 exceeded the Hong Kong Medical Equipment industry which returned -20.2% over the past year.
Return vs Market: 2172 underperformed the Hong Kong Market which returned 27.2% over the past year.
Price Volatility
| 2172 volatility | |
|---|---|
| 2172 Average Weekly Movement | 7.2% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in HK Market | 17.4% |
| 10% least volatile stocks in HK Market | 3.8% |
Stable Share Price: 2172 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2172's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 534 | Zhiyong Xie | www.medneurotech.com |
MicroPort NeuroScientific Corporation engages in the research and development, production, and sale of neuro-interventional medical devices in the People’s Republic of China and internationally. The company offers NUMEN, a coil embolization system; NUMEN FR, a coil detachment system; NUMEN Silk; Tubridge, a flow-diverting stent; Willis, an intracranial stent graft system; Comaneci, an adjustable temporary coil embolization; and Rebridge, an intracranial visualized stent for use in the treatment of hemorrhagic stroke. It also offers NeuroGuard, NuFairy, a absorbable coil embolization system; and liquid embolic agent, a cerebral arteriovenous malformations.
MicroPort NeuroScientific Corporation Fundamentals Summary
| 2172 fundamental statistics | |
|---|---|
| Market cap | HK$5.82b |
| Earnings (TTM) | HK$247.68m |
| Revenue (TTM) | HK$852.71m |
23.5x
P/E Ratio6.8x
P/S RatioIs 2172 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2172 income statement (TTM) | |
|---|---|
| Revenue | CN¥774.66m |
| Cost of Revenue | CN¥200.48m |
| Gross Profit | CN¥574.17m |
| Other Expenses | CN¥349.16m |
| Earnings | CN¥225.01m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.39 |
| Gross Margin | 74.12% |
| Net Profit Margin | 29.05% |
| Debt/Equity Ratio | 0% |
How did 2172 perform over the long term?
See historical performance and comparison